Please assess the completion status of the following clinical trial:

Trial Title: Novel Use Of Hydroxyurea in an African Region With Malaria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pediatric subjects with documented sickle cell anemia (HbSS supported by hemoglobin electrophoresis or by peripheral blood smear showing sickled red blood cells)~* Age range of 1.00-3.99 years, inclusive, at the time of enrollment~* Weight at least 5.0 kg at the time of enrollment~* Willingness to comply with all study-related treatments, evaluations, and follow up~Exclusion Criteria:~* Known chronic medical condition (e.g., HIV, malignancy, active clinical tuberculosis)~* Severe malnutrition determined by impaired growth parameters as defined by WHO (weight for length/height or weight-for-length/height \> 3 z-scores below the median WHO growth standards)~* Pre-existing severe hematological toxicity:~  1. Hb \<4.0 g/dL~ 2. Hb \<6.0 g/dL AND ARC \<100 x 10E9/L~ 3. Hb \<7.0 g/dL AND ARC \<80 x 10E9/L~ 4. Platelets \<80 x 10E9/L~ 5. ANC \<1.0 x 10E9/L~* Alanine transaminase (ALT) or creatinine \>2 times the upper limit of normal for age~* Blood transfusion within 30 days prior to enrollment

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 47 Months
- Healthy Volunteers: f

Study Arms:
- Hydroxyurea (Type: EXPERIMENTAL): Fixed dose 20 ± 2.5 mg/kg/day, administered once a day in tablet form (100mg or scored 1000mg) for twelve months
- Placebo (Type: PLACEBO_COMPARATOR): Fixed dose 20 ± 2.5 mg/kg/day, administered once a day in tablet form (100mg or scored 1000mg) for twelve months

Based on this trial design, predict the completion outcome and termination type (if applicable).